ABT - Abbott Laboratories
NYSE
->
Healthcare
->
Medical Devices
North Chicago,
United States
Type: Equity
ABT price evolution
ABT
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7279 | $6709 | $7835 | $9161 |
| Short term investments | $338 | $320 | $371 | |
| Net receivables | $6565 | $6499 | $6172 | $6020 |
| Inventory | $6570 | $6650 | $6871 | $6673 |
| Total current assets | $22670 | $22664 | $23505 | $24377 |
| Long term investments | $799 | $788 | $799 | $776 |
| Property, plant & equipment | $10154 | $9552 | $9449 | $9282 |
| Goodwill & intangible assets | $32494 | $32559 | $33092 | $32933 |
| Total noncurrent assets | $50544 | $49426 | $49849 | $49417 |
| Total investments | $799 | $1126 | $1119 | $1147 |
| Total assets | $73214 | $72090 | $73354 | $73794 |
| Current liabilities | ||||
| Accounts payable | $4295 | $3961 | $4211 | $4167 |
| Deferred revenue | ||||
| Short long term debt | $1080 | $1051 | $2284 | $2285 |
| Total current liabilities | $13841 | $13042 | $14350 | $14530 |
| Long term debt | $13599 | $14477 | $14562 | $14615 |
| Total noncurrent liabilities | $20546 | $21354 | $21600 | $22032 |
| Total debt | $14679 | $15528 | $16846 | $16900 |
| Total liabilities | $34387 | $34396 | $35950 | $36562 |
| Shareholders' equity | ||||
| Retained earnings | $37554 | $36920 | $36355 | $35868 |
| Other shareholder equity | -$7839 | -$8480 | -$8071 | -$8039 |
| Total shareholder equity | $38827 | $37694 | $37404 | $37232 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7279 | $10170 | $10249 | $7148 |
| Short term investments | $310 | |||
| Net receivables | $6565 | $6218 | $6487 | $6414 |
| Inventory | $6570 | $6173 | $5157 | $5012 |
| Total current assets | $22670 | $25224 | $24239 | $20441 |
| Long term investments | $799 | $766 | $816 | $821 |
| Property, plant & equipment | $10154 | $10278 | $8959 | $9029 |
| Goodwill & intangible assets | $32494 | $33253 | $35970 | $38528 |
| Total noncurrent assets | $50544 | $49214 | $50957 | $52107 |
| Total investments | $799 | $766 | $816 | $821 |
| Total assets | $73214 | $74438 | $75196 | $72548 |
| Current liabilities | ||||
| Accounts payable | $4295 | $4607 | $4408 | $3946 |
| Deferred revenue | ||||
| Short long term debt | $1080 | $2251 | $754 | $220 |
| Total current liabilities | $13841 | $15489 | $13105 | $11907 |
| Long term debt | $13599 | $14522 | $17296 | $18527 |
| Total noncurrent liabilities | $20546 | $22044 | $26067 | $27638 |
| Total debt | $14679 | $16773 | $18050 | $18747 |
| Total liabilities | $34387 | $37752 | $39172 | $39545 |
| Shareholders' equity | ||||
| Retained earnings | $37554 | $35257 | $31528 | $27627 |
| Other shareholder equity | -$7839 | -$8051 | -$8374 | -$8946 |
| Total shareholder equity | $38827 | $36905 | $36024 | $33003 |
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10143 | $9978 | $9747 | |
| Cost of revenue | $4331 | |||
| Gross Profit | $5538 | $5495 | $5416 | |
| Operating activities | ||||
| Research & development | $654 | |||
| Selling, general & administrative | $2762 | |||
| Total operating expenses | $3802 | $3930 | $3907 | |
| Operating income | $1509 | |||
| Income from continuing operations | ||||
| EBIT | $1715 | |||
| Income tax expense | $235 | $261 | $244 | |
| Interest expense | -$59 | -$82 | $153 | |
| Net income | ||||
| Net income | $1436 | $1375 | $1318 | |
| Income (for common shares) | $1318 | |||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $40109 | $43653 | $34608 | |
| Cost of revenue | $19142 | $15003 | ||
| Gross Profit | $22134 | $24511 | $19605 | |
| Operating activities | ||||
| Research & development | $2888 | $2420 | ||
| Selling, general & administrative | $11248 | $9696 | ||
| Total operating expenses | $15332 | $16149 | $14248 | |
| Operating income | $8362 | $5357 | ||
| Income from continuing operations | ||||
| EBIT | $8864 | $5538 | ||
| Income tax expense | $941 | $1373 | $497 | |
| Interest expense | -$293 | $558 | $546 | |
| Net income | ||||
| Net income | $5723 | $6933 | $4495 | |
| Income (for common shares) | $6933 | $4495 | ||
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $1594 | $1436 | $1375 | $1318 |
| Operating activities | ||||
| Depreciation | $813 | $824 | $800 | $806 |
| Business acquisitions & disposals | -$51 | -$786 | ||
| Stock-based compensation | $114 | $117 | $132 | $281 |
| Total cash flows from operations | $3038 | $1877 | $1203 | $1143 |
| Investing activities | ||||
| Capital expenditures | -$755 | -$560 | -$507 | -$380 |
| Investments | -$71 | -$38 | $79 | -$86 |
| Total cash flows from investing | -$824 | -$634 | -$1213 | -$462 |
| Financing activities | ||||
| Dividends paid | -$888 | -$888 | -$890 | -$890 |
| Sale and purchase of stock | -$225 | $54 | -$411 | -$478 |
| Net borrowings | -$939 | -$1506 | $12 | -$42 |
| Total cash flows from financing | -$2052 | -$2340 | -$1289 | -$1410 |
| Effect of exchange rate | $25 | -$29 | -$27 | $8 |
| Change in cash and equivalents | $187 | -$1126 | -$1326 | -$721 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5723 | $6933 | $7071 | $4495 |
| Operating activities | ||||
| Depreciation | $3243 | $3267 | $3538 | $3327 |
| Business acquisitions & disposals | -$837 | $48 | -$53 | $16 |
| Stock-based compensation | $644 | $685 | $640 | $546 |
| Total cash flows from operations | $7261 | $9581 | $10533 | $7901 |
| Investing activities | ||||
| Capital expenditures | -$2202 | -$1777 | -$1885 | -$2177 |
| Investments | -$116 | -$33 | -$96 | -$73 |
| Total cash flows from investing | -$3133 | -$1740 | -$2008 | -$2215 |
| Financing activities | ||||
| Dividends paid | -$3556 | -$3309 | -$3202 | -$2560 |
| Sale and purchase of stock | -$1060 | -$3628 | -$2044 | -$158 |
| Net borrowings | -$2475 | -$699 | -$248 | -$50 |
| Total cash flows from financing | -$7091 | -$7636 | -$5494 | -$2779 |
| Effect of exchange rate | -$23 | -$122 | -$70 | $71 |
| Change in cash and equivalents | -$2986 | $83 | $2961 | $2978 |
News
Fundamentals
| Market cap | $185.36B |
|---|---|
| Enterprise value | $192.76B |
| Shares outstanding | 1.73B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 3.97 |
| Book/Share | 26.91 |
| Cash/Share | 4.20 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.89 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.64 |
| Quick ratio | 1.16 |